GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Diabetes Care · 2023
DOI: 10.2337/dc22-1148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2023. Verfasst von Julien Bezin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pharmacologie, Pôle de Santé Publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Thyroid Neoplasms. Die Arbeit wurde bisher 305-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Agence Nationale de Sécurité du Médicament et des Produits de Santé.
Abstract (Originalsprache)
OBJECTIVE To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND METHODS A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index. RESULTS A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1–3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27–1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04–3.05). CONCLUSIONS In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1–3 years of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service de Pharmacologie, Pôle de Santé Publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
- UMR 1219, Pharmacoepidemiology Team, Bordeaux Population Health Research Center, Inserm, University of Bordeaux, Bordeaux, France.
- Service de Chirurgie ORL, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
- Département de Pharmacologie Médicale et Toxicologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
- INSERM, Université de Montpellier, Institut Desbrest d'Épidémiologie et de Santé Publique, Montpellier, France.
ORCID-Profile: Julien Bezin
Förderung
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
Zitieren
APA
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J. L. (2023). GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. https://doi.org/10.2337/dc22-1148
Vancouver
Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023. doi:10.2337/dc22-1148
BibTeX
@article{Bezin2023,
author = {Bezin, Julien and Gouverneur, Amandine and Pénichon, Marine and Mathieu, Clément and Garrel, Renaud and Hillaire-Buys, Dominique and Pariente, Antoine and Faillie, Jean-Luc},
title = {GLP-1 Receptor Agonists and the Risk of Thyroid Cancer},
journal = {Diabetes Care},
year = {2023},
doi = {10.2337/dc22-1148}
}
EUVIMED